日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge

出院时接受四联药物治疗的射血分数降低型心力衰竭住院患者的一年预后

Greene, Stephen J; Xu, Haolin; Chiswell, Karen; Felker, G Michael; Lewsey, Sabra C; Divanji, Punag H; Goertz, Hans-Peter; Heitner, Stephen B; Shreay, Sanatan; Pandey, Ambarish; Yancy, Clyde W; Butler, Javed; Fonarow, Gregg C

Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy

社会人口学特征对梗阻性肥厚型心肌病预后的影响

Reza, Nosheen; Butzner, Michael; Batra, Kirti; Amos, Qiana; Buikema, Ami; Shreay, Sanatan; Owens, Anjali

Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023

2016年至2023年美国肥厚型心肌病流行病学研究

Butzner, Michael; ElHabr, Andrew K; Farajkhah, Kian; Chhatwal, Jagpreet; Ayer, Turgay; Gebrehiwet, Paulos; Shreay, Sanatan; Riello, Ralph J 3rd; Desai, Nihar R; Owens, Anjali T; Abraham, Theodore; Masri, Ahmad

Longitudinal analyses of healthcare resource utilization and costs among patients with obstructive hypertrophic cardiomyopathy

对梗阻性肥厚型心肌病患者的医疗资源利用和成本进行纵向分析

Reza, Nosheen; Butzner, Michael; Batra, Kirti; Amos, Qiana; Buikema, Ami; Shreay, Sanatan; Owens, Anjali

Differences in Healthcare Resource Use and Cost by Pharmacotherapy Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Real-World Analysis of Claims Data

症状性梗阻性肥厚型心肌病患者药物治疗在医疗资源利用和成本方面的差异:基于真实世界索赔数据的分析

Butzner, Michael; Papademetriou, Eros; Potluri, Ravi; Liu, Xing; Shreay, Sanatan

An evidence review and gap analysis for obstructive hypertrophic cardiomyopathy

阻塞性肥厚型心肌病证据回顾与差距分析

Butzner, Michael; Aronitz, Elise; Cameron, Heather; Tantakoun, Krista; Shreay, Sanatan; Drudge, Christopher

Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database

非酒精性脂肪性肝炎成人患者的住院费用和死亡风险:一项基于法国国家医院数据库的分析

Boursier, Jérôme; Shreay, Sanatan; Fabron, Cecile; Torreton, Elodie; Fraysse, Jeremy

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial

一项 III 期随机试验评估了 idelalisib 对复发性慢性淋巴细胞白血病患者健康相关生活质量的影响

Ghia, Paolo; Coutre, Steven E; Cheson, Bruce D; Barrientos, Jacqueline C; Hillmen, Peter; Pettitt, Andrew R; Zelenetz, Andrew D; Shreay, Sanatan; Hallek, Michael; Furman, Richard R

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

idelalisib治疗复发性、利妥昔单抗和烷化剂难治性滤泡性淋巴瘤患者的疗效和安全性:一项II期研究的亚组分析

Salles, Gilles; Schuster, Stephen J; de Vos, Sven; Wagner-Johnston, Nina D; Viardot, Andreas; Blum, Kristie A; Flowers, Christopher R; Jurczak, Wojciech J; Flinn, Ian W; Kahl, Brad S; Martin, Peter; Kim, Yeonhee; Shreay, Sanatan; Will, Matthias; Sorensen, Bess; Breuleux, Madlaina; Zinzani, Pier Luigi; Gopal, Ajay K

Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels

美国医疗保险终末期肾病(ESRD)报销制度和促红细胞生成素(ESA)标签变更期间,慢性透析患者的红细胞(RBC)输注率

Cappell, Katherine A; Shreay, Sanatan; Cao, Zhun; Varker, Helen V; Paoli, Carly J; Gitlin, Matthew